TRIUMPH-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Clinical Trials Dispatch
SUSTAIN-6 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SUSTAIN-6 met its primary endpoint and did not meet one of its hierarchically tested secondary endpoints, a result which appears in the paper and in almost none of the reporting. Under a pre-specified testing hierarchy a failure at that point formally precludes claims on the endpoints below it, whatever the nominal p-values show.
The endpoint hierarchy was pre-specified in the statistical analysis plan and is reproduced in the supplementary appendix. Readers relying on the abstract will not see it. The Journal reads the analysis plan before the paper for exactly this reason.
Cross-trial comparison is the commonest error in coverage of this field. Populations differ in baseline weight, diabetes status and lifestyle-intervention intensity; durations differ; estimands differ. Two programmes reporting 15% and 20% may or may not reflect a difference between the drugs, and only a head-to-head trial settles it.
"The mean is not the interesting part and it never has been," said Dr Rafał Sikorski, toxicologist, Medical University of Warsaw. "Show me the decile plot. That is where the clinical question lives."
The Journal has asked the investigators whether the decile-level responder data will be released. The department will report the answer.
Note
Trial results describe populations, not individuals. Nothing in this item is clinical advice.
Related coverage
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Side effects, cost, supply, target: four reasons with four trajectories
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
STEP 4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURMOUNT-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.